LinkedInXFacebook
Subscribe
Orthopedics This Week
  • Opinions
  • |My Feed
  • |Events
  • |Company Directory
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Press Releases/Company News/Roots Equity Group Acquires Innovasis Medical;Appoints Matt Stuttle as Chief Executive Officer
Press ReleaseCompany News

Roots Equity Group Acquires Innovasis Medical;Appoints Matt Stuttle as Chief Executive Officer

By TJ HalvorsonNovember 14, 2025 2 min read Premium comments

Advertisement

Roots Equity Group Acquires Innovasis Medical;Appoints Matt Stuttle as Chief Executive Officer
Courtesy of Innovasis, Inc.
Press Release

LOS ANGELES, Calif., November 13, 2025 — Roots Equity Group, a West Coast–based family office investment firm, today announced the acquisition of Innovasis, a Salt Lake City–based, vertically integrated medical device company specializing in the design, manufacture, and distribution of implants used to treat a wide range of musculoskeletal (MSK) and orthopedic disorders.

As part of the transaction, Matt Stuttle, a seasoned healthcare executive and medical technology industry veteran, has been appointed Chief Executive Officer. “I’m honored to lead this incredible organization and its world-class team into the next phase of transformative growth,” said Stuttle. “Our integrated capabilities and commitment to innovation position us to deliver life-changing therapies for years to come. As we continue to expand our platform and reach, we remain unwavering in our mission to provide differentiated, high-quality treatment solutions that improve patient outcomes and support the healthcare professionals who depend on us.”

Innovasis’ long-time Chairman who is transitioning out of the role expressed strong support for the leadership change and optimism about the company’s future. “I couldn’t be more excited about what lies ahead for Innovasis. I am incredibly proud of our team and what they have achieved over nearly two decades. Our implants have helped thousands of patients around the world, yet we truly believe the best is still to come.” “I certainly understand the critical need for continued innovation.” “Providing surgeons, hospitals, and—most importantly—patients and their families with meaningful, lifechanging therapies is essential. I have full confidence in Matt’s leadership and deep appreciation for the strong capital partners at Roots Equity Group who will guide Innovasis into its next chapter.”

Financial terms of the transaction were not disclosed.

About Roots Equity Group
Roots Equity Group and its investment partner comprise a family office investment firm dedicated to partnering with high-quality companies across the healthcare, industrial technology, and essential services sectors. The firm focuses on long-term, operationally driven investments designed to foster sustainable innovation, strategic growth, and enduring value creation. Through its collaborative approach and deep industry expertise, Roots Equity Group supports a diverse portfolio of businesses committed to building lasting impact.

About Innovasis
Innovasis is a leading medical device manufacturer specializing in innovative spinal and
musculoskeletal treatment solutions. Headquartered in Salt Lake City, Utah, the company
designs, manufactures, and markets high-quality implants and surgical systems used by
hospitals, outpatient surgical centers, and surgeons worldwide. Innovasis is committed to
advancing patient outcomes through clinical collaboration, technological innovation, and
dependable product performance.

Media Contact:
Andy Curtis
Director of Marketing, Innovasis
acurtis@innovasis.com
(801) 261-2236

Author

TH
TJ Halvorson

The De Angelis Group | Orthopedics This Week | MSK Innovations

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

Orthopedics This Week’s mission is to connect the orthopedic community with the people, ideas, and innovations shaping the future of musculoskeletal care.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Opinions
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, opinions, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy